Search Results - technology+classifications+%3e+life+sciences+%3e+vaccines

3 Results Sort By:
TROVE: A Translational Resource for Omics-Based Validation of Expression Datasets
Translational Resource for Omics-Based Validation of Expression (TROVE) is a solution-oriented query-able disease database that integrates various -omic data from animals and humans, reflective of the One Health paradigm. The innovation is focused on dataset integration and identification, to immediately provide targeted solutions for identified infection/immunity...
Published: 7/24/2023   |   Inventor(s): Gayatri Vedantam, Virinchipuram Viswanathan, Bryan Roxas
Keywords(s):  
Category(s): Technology Classifications > Software & Information Technology > Bioinformatics, Technology Classifications > Software & Information Technology > Health IT, Technology Classifications > Software & Information Technology, Technology Classifications > Life Sciences > Biomarkers, Technology Classifications > Life Sciences > Diagnostics, Technology Classifications > Life Sciences > Vaccines
Viral Vector for Developing Oral Vaccines and Therapeutics Against Diseases in Aquatic Animals
This technology uses a genetically engineered replication deficient virus as a vector to deliver genes encoding vaccine (i.e. antigen) or therapeutic nucleic acid (e.g. RNAi molecules). The vaccine gene can be purified and used as an injectable vaccine in fin fish. In fin fish, the vaccine gene will express the antigen and immunize the vaccinated fish....
Published: 5/14/2024   |   Inventor(s): Arun Dhar, Arjoneel Dhar, Rod Alenton
Keywords(s):  
Category(s): Technology Classifications > Agriculture & Horticulture > Aquaculture, Technology Classifications > Life Sciences > Vaccines
Cytomegalovirus Vaccine Backbone that Cannot be Reactivated
This technology describes a Cytomegalovirus (CMV) vaccine vector with mutations or deletions in newly-found intronic promoters that are important for CMV reactivation. Background: Cytomegalovirus (CMV) is a virus within the herpes family that is extremely common. Nearly 50% of adults will have contracted CMV by the time they reach 40 years old. Once...
Published: 4/14/2023   |   Inventor(s): Felicia Goodrum Sterling, Nathaniel Moorman, Jeremy Kamil
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Vaccines